Open AccessA first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma
Author(s) -
John de Groot,
Martina Ott,
Jun Wei,
Cynthia Kassab,
Dexing Fang,
Hinda Najem,
Barbara O’Brien,
Shiao-Pei Weathers,
Carlos Kamiya Matsouka,
Nazanin Majd,
Rebecca Harrison,
Gregory N. Fuller,
Jason T. Huse,
James P. Long,
Raymond Sawaya,
Ganesh Rao,
Tobey J. MacDonald,
Waldemar Priebe,
Michael DeCuypere,
Amy B. Heimberger
Publication year - 2022
Publication title -
cns oncology
Language(s) - English
Resource type - Journals
eISSN - 2045-0915
pISSN - 2045-0907
DOI - 10.2217/cns-2022-0005
Subject(s) - medicine , nausea , adverse effect , gastroenterology , cmax , pharmacokinetics , immune system , phases of clinical research , toxicity , urology , oncology , immunology